


PHARMACEUTICAL 2023

Lexaria Bioscience Corp. Rank 162 of 446







PHARMACEUTICAL 2023

Lexaria Bioscience Corp. Rank 162 of 446



The relative strengths and weaknesses of Lexaria Bioscience Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lexaria Bioscience Corp. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 77% points. The greatest weakness of Lexaria Bioscience Corp. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is 143%, being 100% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	6,978
Cost of Goods Sold	72
Intangible Assets	0
Liabilities, Current	194
Liabilities, Non-Current	7.4
Other Assets	541
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	255
Property and Equipment	316
Research and Development	1,843
Selling, General and Administrative Expense	5,725

Output Variable	Value in 1000 USD
Assets	7,834
Liabilities	201
Expenses	7,639
Revenues	255
Stockholders Equity	7,632
Net Income	-7,384
Comprehensive Net Income	-7,384
Economic Capital Ratio	143%

